Multicenter fase 1-2 trial of dinutuximab beta and low-dose interleukin-2 after haploidentical stem cell transplantation for relapsed neuroblastoma

Patients with relapsed high-risk neuroblastoma (rHR-NB) have a poor prognosis. A phase 1-2 trial in Germany and Austria evaluated transplantation of haploidentical stem cells (haploSCT) followed by activation of natural killer cells by the anti-GD2 antibody dinutuximab beta (DB) plus subcutaneous interleukin-2 (scIL2) in patients with rHR-NB. The study showed that DB therapy after haplo-SCT in patients with rHR-NB is feasible, with low risk of inducing GVHD, and results in long-term remissions likely attributable to increased antineuroblastoma activity of donor-derived effector cells.